A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940-001) - Trial NCT05933577
Access comprehensive clinical trial information for NCT05933577 through Pure Global AI's free database. This Phase 3 trial is sponsored by Merck Sharp & Dohme LLC and is currently Recruiting. The study focuses on Melanoma. Target enrollment is 1089 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Merck Sharp & Dohme LLC
Timeline & Enrollment
Phase 3
Jul 19, 2023
Sep 26, 2030
Primary Outcome
Recurrence-Free Survival (RFS)
Summary
The purpose of this study is to learn if V940 which is an individualized neoantigen therapy
 (INT; formerly, called messenger ribonucleic acid [mRNA]-4157) with pembrolizumab (MK-3475)
 is safe and prevents cancer from returning in people with high-risk melanoma. Researchers
 want to know if V940 with pembrolizumab is better than receiving pembrolizumab alone at
 preventing the cancer from returning.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05933577
Non-Device Trial